Sign inJoin waitlistJoin the waitlist

Asrar Alahmadi

Associate Professor · Ohio State University Hospital

Credentials: · · · · ·

History

Ohio State University Hospital
Present

Hematology and Medical Oncology
Case Western Reserve University
2017–2020
Internal Medicine
2014–2017
KING ABDULAZIZ UNIV, COLLEGE OF MEDICINE & ALLIED SCIENCES, JEDDAH, SAUDI ARABIA
2007–2011

Research

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study
JAMA Oncology · 2021 · 141 citations
Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer
Journal of the National Comprehensive Cancer Network · 2023 · 26 citations
Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer
Molecular Cancer Therapeutics · 2023 · 24 citations

Carolyn Presley
14 papers
Dwight Owen
14 papers
Mingjia Li
13 papers
David Carbone
12 papers
KH
Kai He
12 papers
Peter Shields
12 papers
Jacob Kaufman
11 papers
Regan Memmott
11 papers
GO
Gregory Otterson
8 papers
Jinesh Gheeya
8 papers
Logan Roof
7 papers
Afshin Dowlati
4 papers

Clinical trials

Prospective Multiomic Analysis in Small-Cell Lung Cancer
Principal investigator · Not yet recruiting
Ohio State University Comprehensive Cancer Center
2026–2028
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
Principal investigator · Recruiting · Phase 2
Asrar Alahmadi
2026–2027
Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer
Principal investigator · Completed · Phase 2
Ohio State University Comprehensive Cancer Center
2020–2023
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
Site PI · Recruiting · Phase 2
PrECOG, LLC.
2026–2030